Abstract

As numerous bodies of research have characterized the adipocytokine adiponectin (ACRP30) as an anti-diabetic compound, this work serves as an analysis to partly elucidate the potential usage of supplementary adiponectin as a therapeutic compound in the treatment of type II diabetes mellitus. In this work, a meta-analysis was conducted to centralize large amounts of data on adiponectin’s insulin sensitizing characteristics in conjunction with like-minded studies utilizing metformin treatment as the diabetic standard of care. Upon comparison of fasting glucose, fasting insulin, and glucose tolerance test area under the curve reduction percentages, it is quite clear that ACRP30 has significant insulin enhancing properties in mouse models rivaling SOC metformin. Yet, inconsistent dosing comparisons in this analysis, the unknowns of chronic hyperadiponectinemia in humans, as well as variations in age of human diabetic patients warrant further standardized research to suggest that adiponectin supplementation can rival that of modern-day standard of care for type II diabetes mellitus.

Thesis Completion

2022

Semester

Spring

Thesis Chair/Advisor

Flory, David

Degree

Bachelor of Science (B.S.)

College

College of Undergraduate Studies

Department

Interdisciplinary Studies

Language

English

Access Status

Open Access

Release Date

5-1-2022

Download

Included in

Endocrinology Commons

Share

COinS
 

Accessibility Statement

This item was created or digitized prior to April 24, 2027, or is a reproduction of legacy media created before that date. It is preserved in its original, unmodified state specifically for research, reference, or historical recordkeeping. In accordance with the ADA Title II Final Rule, the University Libraries provides accessible versions of archival materials upon request. To request an accommodation for this item, please submit an accessibility request form.